These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1898537)

  • 1. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial occlusions.
    Dawson KJ; Hamilton G
    Radiology; 1991 Jan; 178(1):283-4. PubMed ID: 1898537
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial.
    Meyerovitz MF; Goldhaber SZ; Reagan K; Polak JF; Kandarpa K; Grassi CJ; Donovan BC; Bettmann MA; Harrington DP
    Radiology; 1990 Apr; 175(1):75-8. PubMed ID: 2107563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing trends in thrombolytic therapy for lower limb ischaemia.
    Andaz S; Scurr J
    Int Angiol; 1994 Jun; 13(2):93-5. PubMed ID: 7963882
    [No Abstract]   [Full Text] [Related]  

  • 4. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy.
    Semba CP; Bakal CW; Calis KA; Grubbs GE; Hunter DW; Matalon TA; Murphy TP; Stump DC; Thomas S; Warner DL
    J Vasc Interv Radiol; 2000 Mar; 11(3):279-87. PubMed ID: 10735420
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of tissue plasminogen activator and urokinase in a canine model of prosthetic graft thrombosis.
    Curl GR; Jakubowski JA; Nabseth DC; Bush HL
    Arch Surg; 1986 Jul; 121(7):782-8. PubMed ID: 3087327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thrombotic and thromboembolic occlusions of leg arteries and bypasses. Short-term versus long-term lysis].
    Zwaan M; Rinast E; Kummer-Kloess D; Weiss HD; Gmelin E
    Rofo; 1993 Jun; 158(6):536-41. PubMed ID: 8507844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis].
    Vignali C; Cioni R; Mascalchi M; Russo R; Palla A; Lencioni R; Napoli V; Bartolozzi C
    Radiol Med; 1994; 88(1-2):93-9. PubMed ID: 8066262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
    Curl GR; Jakubowski JA; Deykin D; Bush HL
    Circulation; 1986 Sep; 74(3 Pt 2):I21-4. PubMed ID: 3091289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urokinase infusion in total occlusion of peripheral vascular disease.
    Gaston JG; Sensarma PK; Sadiq S
    Kans Med; 1991 Mar; 92(3):73-5. PubMed ID: 2041277
    [No Abstract]   [Full Text] [Related]  

  • 11. Pulsed-spray thrombolysis of arterial and bypass graft occlusions.
    Valji K; Roberts AC; Davis GB; Bookstein JJ
    AJR Am J Roentgenol; 1991 Mar; 156(3):617-21. PubMed ID: 1825256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation of published work.
    Ouriel K; Kandarpa K
    J Endovasc Ther; 2004 Aug; 11(4):436-46. PubMed ID: 15298504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts.
    Comerota AJ; Weaver FA; Hosking JD; Froehlich J; Folander H; Sussman B; Rosenfield K
    Am J Surg; 1996 Aug; 172(2):105-12. PubMed ID: 8795509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolysis with recombinant tissue plasminogen activator in late saphenous vein graft thrombosis.
    Blanck Z; Cheirif J; Blick DR; Harris SL; Heibig J
    Am Heart J; 1990 Apr; 119(4):952-3. PubMed ID: 2138846
    [No Abstract]   [Full Text] [Related]  

  • 15. Thrombolytic therapy with recombinant human tissue-type plasminogen activator: a comparison of two doses.
    Risius B; Graor RA; Geisinger MA; Zelch MG; Lucas FV; Young JR
    Radiology; 1987 Aug; 164(2):465-8. PubMed ID: 3110860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress on thrombolytic treatment].
    Kazama M
    Nihon Naika Gakkai Zasshi; 1991 Jun; 80(6):885-90. PubMed ID: 1919203
    [No Abstract]   [Full Text] [Related]  

  • 17. Intra-arterial thrombolysis. A surgical view.
    Ricotta J
    Circulation; 1991 Feb; 83(2 Suppl):I120-1. PubMed ID: 1991394
    [No Abstract]   [Full Text] [Related]  

  • 18. Transgraft hemorrhage: a serious complication of low-dose thrombolytic therapy.
    Perler BA; Kinnison M; Halden WJ
    J Vasc Surg; 1986 Jun; 3(6):936-8. PubMed ID: 2940380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Local intra-arterial thrombolysis. Results in arterial thromboses and graft occlusions].
    Hansen AK; Egeblad MR; Klaerke A
    Ugeskr Laeger; 1997 Mar; 159(13):1950-3. PubMed ID: 9123634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1.
    Nicholls SC; Hoffer EK; Chandler WL
    Blood Coagul Fibrinolysis; 2003 Dec; 14(8):729-33. PubMed ID: 14614351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.